Technology

A range of packages is available for industry partners to implement charity giving.

Novartis announces that its lung cancer drug, Zykadia, gained European Union approval.

Research from MediciGlobal shows that patients who actively sought clinical trial involvement through its online recruitment model had a 38% lower relative risk of drop out across four studies compared to those who were recruited by sites, with divergence across visits.

The US Court of Appeals granted Amgen’s request to block Novartis’ Neupogen biosimilar, Zarxio, from the US market until the court resolves litigation between the two companies.

May 7, 2015.

May 7, 2015.

May 6, 2015.

May 6, 2015.

May 6, 2015.

Alexion announces it will expand its rare disease pipeline with a definitive agreement to acquire Synageva.

Eleven of the leading US biosimilar developers have collaborated to form the Biosimilars Forum, a nonprofit organization formed to expand patient access to biosimilars.

May 5, 2015.

Dave Campbell offers some tactics that pharma leaders can implement to stem the continued global threat of counterfeit drugs.

April 30, 2015.

Perrigo rejected Mylan’s second proposal for an acquisition valued at more than $34 billion, saying that the offer was too low to consider.

Takeda Pharmaceutical agrees to pay $2.4 billion to settle lawsuits from patients and family members who said the diabetes drug Actos caused bladder cancer.

FDA releases long-awaited guidance documents regarding the assessment of biosimilarity.

April 28, 2015.

April 28, 2015.

April 27, 2015.

April 27, 2015.

The industry continues to puzzle over FDA's proposed regulation of mobile medical apps (MMAs), writes Jill Wechsler.

April 24, 2015.

April 24, 2015.

April 23, 2015.

Teva announces that it would pay up to $40 billion in cash and stock to acquire Mylan.

The European Medicines Agency releases findings from marketing authorization application analysis.

April 21, 2015.

The agency has released draft guidance on providing regulatory submissions in regards to promotional labeling and advertising materials.

At the request of FDA, US Marshals seize unapproved prescription drugs from Florida distributor.